Maharashtra FDA Suspends 1,376 Licenses in Statewide Crackdown
The Maharashtra FDA has suspended 1,376 food and drug licenses and seized goods worth ₹63.8 crore in a recent enforcement drive.
1,376 licenses suspended by Maharashtra FDA during enforcement.
Goods worth ₹63.8 crore seized, including food, drugs, and cosmetics.
Over 11,600 establishments inspected across the state.
In a significant enforcement action, the Maharashtra Food and Drug Administration (FDA) has suspended 1,376 licenses related to food and drugs, alongside seizing products valued at approximately ₹63.8 crore. This crackdown is part of a broader initiative aimed at ensuring food safety and drug regulation across the state, with the operations concluding on November 3.
The enforcement drive, which spanned from September 1 to November 3, involved rigorous inspections of over 11,600 establishments throughout Maharashtra. The FDA's efforts are particularly focused on maintaining standards in food safety and drug efficacy, especially as the festive season approaches, prompting increased scrutiny of food products and pharmaceuticals.
Among the seized items, the FDA reported that the value of spices and condiments alone amounted to ₹21.09 crore. This highlights the scale of the operation and the commitment of the FDA to eliminate unsafe products from the market. The enforcement figures for the Drugs Department specifically cover the month of October, further underscoring the comprehensive nature of the FDA's efforts.
The implications of this crackdown are significant for public health and safety in Maharashtra. By suspending licenses and removing unsafe products from circulation, the FDA aims to protect consumers from potentially harmful food and drugs. This initiative is expected to foster greater compliance among businesses and enhance overall safety standards in the food and drug sectors.
Looking ahead, the Maharashtra FDA plans to continue its inspections and enforcement activities to ensure that all establishments adhere to regulatory standards. Stakeholders in the food and drug industries are advised to review their compliance measures in light of these recent actions, as further inspections are likely to follow in the coming months.
